期刊文献+

Stathmin/Oncoprotein18(Op18)基因在人骨肉瘤中的表达及其意义

Expression and Significance of Stathmin/Oncoprotein 18(Op18) Gene in Human Osteosarcoma
原文传递
导出
摘要 目的:探讨stathmin/oncoprotein 18(Op18)基因在人骨肉瘤中的表达规律及意义。方法:分别采用免疫组化法和Western blot法检测10例正常骨组织和56例骨肉瘤中stathmin蛋白的表达。结果:免疫组化法检测stathmin蛋白在正常骨组织、低级别骨肉瘤(G1级组)及高级别骨肉瘤(G2级组)中阳性表达率分别为20%、65%、100%。正常骨组织分别与G1级组、G2级组比较,均有显著性差异(P﹤0.05);G1级组与G2级组比较,有显著差异(P<0.05)。Western blot法检测显示,stathmin蛋白在正常骨组织、G1级组、G2级组表达相对值分别为(0.34±0.15)、(0.68±0.21)、(0.90±0.17)。正常骨组织分别与G1级级组、G2级组比较,差异均有显著性(P<0.01),G1级组与G2级组比较,差异有显著性(P<0.01)。结论:Stathmin在骨肉瘤中过表达,与骨肉瘤的发生及发展密切相关。 Objective: To investigate the expression of stathmin/oncoprotein 18 (Op18) in human osteosarcoma and its relation to biological behaviors ofosteosarcoma. Methods: The stathmin protein expressions of 56 cases with human osteosarcoma and 10 cases of normal bone tissues were examined by immunohistochemical staining and Western blot methods. Results: The positive rate of stathmin in normal human bone tissues, G1 grade and G2 grade were 20%, 65%, 100% respectively. The difference between normal human bone tissues and G1 grade, G2 grade were significant (P〈0.05)respectively; the difference between G1 grade and G2 grade were significant(P〈0. 05). Expression of stathmin in normal human bone tissues, GI grade and G2 grade were (0.34± 0.15), (0.68± 0.21 ), (0.90± 0.17) respectively. The difference be-tween normal human bone tissues and G1 grade, G2 grade were significant (P〈0.01) respectively; the difference between G1 grade and G2 grade were significant (P〈0.01). Conclusion: Overexpression of stathmin plays an important role in development and progression of human osteosarcoma.
出处 《现代生物医学进展》 CAS 2011年第19期3709-3712,共4页 Progress in Modern Biomedicine
基金 黑龙江省教育厅科学技术研究项目(No.11551168)
关键词 骨肉瘤 stathmin/oncoprotein 18 免疫组化法 WESTERN BLOT Osteosarcoma Stathmin/oncoprotein 18 Western blot Immunohistochemical staining
  • 相关文献

参考文献15

  • 1Mistry S J, Berdaam C, Atweh GF. Development of ribozymes that target stathmin, a major regulator of the mitotic spindle [J]. Anti-sense Nucleic Acid Drug Dev, 2001, 11(1): 41-49.
  • 2Stephan A, Vorburger, Kelly K. Hunt. Adenoviral gene therapy. The Oneologist, 2002,7(1):46-59.
  • 3Ng DC, Zhao TT, Yeap YY, et al.c-Jun N-terminal kinase phosphorylation ofstathmin confers protection against cellular stress [J]. J Bio chem, 2010,285(37):29001-29013.
  • 4Kouzu Y, Uzawa K, Koike H, et al. Overexpression of stathmin in oral squamous-cell careinoma correlation with tumour progression and poor prognosis[J]. Br J Cancer,2006,94(5):717-723.
  • 5Chen G, Wang H, Charib TG, et al. Overexpression of oncoprotein 18 correlates with poor differentiation in lung adenocarcinomas [J]. Mol Cell Proteomies, 2003,2(2): 107 - 116.
  • 6Zhang D, Tari AM, Akar AU. Silencing kinase-interacting stathmin gene enhances erlotinib sensitivity by inhibiting Ser(1) p27 phosphorylation in epidermal growth factor receptor-expressing breast cancer [J]. Mol Cancer Ther, 2010, 9(11):3090-3099.
  • 7Mistry S J, Atweh GF. Therapeutic interaetions between stathmin inhibition and chemotherapeutic agenfs in prostate cancer[J]. Mol Cancer Ther,2006,5(12):3248-3257.
  • 8Akao Y, Kusakabe S, Banno Y, et al. Ceramide accumulation is inde-pendent of camptothecin-induced apoptosis in prostate cancer LNCaPcells[J]. Biochem Biophys Res Commun, 2002,294:363-370.
  • 9Balachandran R. Welsh M J, Day BW. Altered levels and regulation of stathmlnin paclitaxel-resistant ovarian cancer cells [J]. Oneogene, 2003,22(55):8924-8930.
  • 10Tamminga CA, Sobel A, Curmi PA, et al. Phosphory lation of the tubulin-binding protein, stathmin, by Cdk5 and MAP kinases in the brain[J]. J Neurochem,2006,99(1): 237-250.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部